Roivant Sciences Ltd.
HealthcareNASDAQ:ROIV · NASDAQ Global Market
+$0.57 today
Vol 5.27M · Avg 5.63M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-6.6%
avg -8.5%
ROIC
-23.5%
avg -29.9%
ROA
-5.2%
avg -0.7%
Analysis
ROA is currently the strongest return metric at -5.2% versus its period average of -0.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Mayukh Sukhatme | President, Chief Investment Officer & Director | $81.64M | — | 50 | $18.68M | 2.60% |
Eric Venker | President & Chief Executive Officer of Immunovant | $6.67M | — | 39 | $4.44M | 0.62% |
Matthew Gline | Chief Executive Officer & Director | $5.72M | — | 42 | $16.74M | 2.33% |
Richard Pulik | Chief Financial Officer | $1.55M | — | 46 | $278,549.00 | 0.04% |
Jennifer Humes | Chief Accounting Officer | $324,640.00 | — | 44 | $113,364.00 | 0.02% |
Frank Torti | President & Vant Chair | — | — | 47 | $13.58M | 1.89% |
Huafeng Xu | Chief Technology Officer | — | — | — | — | — |
Alex Gasner | Executive Vice President of Roivant Health | — | — | — | — | — |
Ian Rosenblum | Chief Information Officer | — | — | — | — | — |
Josh Chen | General Counsel | — | — | — | — | — |
Kelly Graff | Head of People | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
80
$645.51M
Net Sentiment
$645.51M
Net selling
Most Active
Venker Eric
16 transactions
1–10 of 80
Analysis
Insiders reported 0 buys worth $0.00 and 80 sells worth $645.51M over the last 12 months. That adds up to net selling of $645.51M. Venker Eric was the most active insider with 16 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | -9.4% (8yr)6 analysts |
| Revenue | N/A | N/A | +11.2% | +86.1% (8yr)3 analysts |
| Net Income | N/A | N/A | N/A | -11.5% (8yr)3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +11.2% over three years. Forward estimates point to Revenue at +86.1% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$32.72B
Royalty Pharma plc
NASDAQ:RPRX
$23.72B
Exact Sciences Corporation
EXAS
$20.03B
Moderna, Inc.
NASDAQ:MRNA
$20.03B
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.64B
Ascendis Pharma A/S
NASDAQ:ASND
$13.67B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.17B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.17B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.82B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$210.23M
Who manages ROIV?
Roivant Sciences Ltd. (ROIV) lists 11 active executives. The top listed executive is Frank Torti, President & Vant Chair.
Are ROIV insiders buying or selling?
Recent insider activity shows net selling of $817.93M.
Explore More
Continue the stock analysis
Jump to another research area for this company.